NCT01705249 - Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women | Biotech Hunter

Enrollment

191

Participants

Timeline

Start Date

August 14, 2001

Primary Completion Date

June 6, 2003

Study Completion Date

June 6, 2003

Conditions

MenopauseHealthy

Interventions

DRUG

1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)

After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.

Trial Locations (19)

Unknown

Novo Nordisk Investigational Site, Kristiansand

Novo Nordisk Investigational Site, Kristiansund

Novo Nordisk Investigational Site, Larvik

0309

Novo Nordisk Investigational Site, Oslo

NO-7012

Novo Nordisk Investigational Site, Trondheim

503 32

Novo Nordisk Investigational Site, Borås

411 19

Novo Nordisk Investigational Site, Gothenburg

418 33

Novo Nordisk Investigational Site, Gothenburg

434 30

Novo Nordisk Investigational Site, Kungsbacka

581 85

Novo Nordisk Investigational Site, Linköping

582 20

Novo Nordisk Investigational Site, Linköping

582 22

Novo Nordisk Investigational Site, Linköping

602 22

Novo Nordisk Investigational Site, Norrköping

602 32

Novo Nordisk Investigational Site, Norrköping

193 30

Novo Nordisk Investigational Site, Sigtuna

151 23

Novo Nordisk Investigational Site, Södertälje

111 37

Novo Nordisk Investigational Site, Stockholm

111 57

Novo Nordisk Investigational Site, Stockholm

451 30

Novo Nordisk Investigational Site, Uddevalla